174 related articles for article (PubMed ID: 33288852)
1. Mesalazine granule formulation improves clinical data in Crohn's disease compared with tablet formulation.
Tamura S; Ishida N; Miyazu T; Onoue S; Tani S; Yamade M; Hamaya Y; Iwaizumi M; Osawa S; Furuta T; Sugimoto K
Sci Rep; 2020 Dec; 10(1):21353. PubMed ID: 33288852
[TBL] [Abstract][Full Text] [Related]
2. Prolonged-release mesalazine: a review of its therapeutic potential in ulcerative colitis and Crohn's disease.
Clemett D; Markham A
Drugs; 2000 Apr; 59(4):929-56. PubMed ID: 10804042
[TBL] [Abstract][Full Text] [Related]
3. Systematic review: the potential influence of mesalazine formulation on maintenance of remission in Crohn's disease.
Steinhart AH; Forbes A; Mills EC; Rodgers-Gray BS; Travis SP
Aliment Pharmacol Ther; 2007 Jun; 25(12):1389-99. PubMed ID: 17539978
[TBL] [Abstract][Full Text] [Related]
4. A controlled trial comparing ciprofloxacin with mesalazine for the treatment of active Crohn's disease. Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID).
Colombel JF; Lémann M; Cassagnou M; Bouhnik Y; Duclos B; Dupas JL; Notteghem B; Mary JY
Am J Gastroenterol; 1999 Mar; 94(3):674-8. PubMed ID: 10086650
[TBL] [Abstract][Full Text] [Related]
5. Mesalazine for the treatment of inflammatory bowel disease.
Criscuoli V; Modesto I; Orlando A; Cottone M
Expert Opin Pharmacother; 2013 Aug; 14(12):1669-78. PubMed ID: 23767798
[TBL] [Abstract][Full Text] [Related]
6. Budesonide and mesalazine in active Crohn's disease: a comparison of the effects on quality of life.
Thomsen OO; Cortot A; Jewell D; Wright JP; Winter T; Veloso FT; Vatn M; Persson T; Pettersson E;
Am J Gastroenterol; 2002 Mar; 97(3):649-53. PubMed ID: 11922560
[TBL] [Abstract][Full Text] [Related]
7. A comparison of budesonide and mesalamine for active Crohn's disease. International Budesonide-Mesalamine Study Group.
Thomsen OO; Cortot A; Jewell D; Wright JP; Winter T; Veloso FT; Vatn M; Persson T; Pettersson E
N Engl J Med; 1998 Aug; 339(6):370-4. PubMed ID: 9691103
[TBL] [Abstract][Full Text] [Related]
8. Mesalazine (Mesasal/Claversal) 1.5 g b.d. vs. placebo in the maintenance of remission of patients with Crohn's disease.
Thomson AB; Wright JP; Vatn M; Bailey RJ; Rachmilewitz D; Adler M; Wilson-Lynch KA
Aliment Pharmacol Ther; 1995 Dec; 9(6):673-83. PubMed ID: 8824656
[TBL] [Abstract][Full Text] [Related]
9. Investigation of a High-Dose pH-Dependent-Release Mesalazine on the Induction of Remission in Active Crohn's Disease.
Suzuki Y; Iida M; Ito H; Tachikawa N; Hibi T
Drugs R D; 2016 Mar; 16(1):35-43. PubMed ID: 26883035
[TBL] [Abstract][Full Text] [Related]
10. Systematic review: the use of mesalazine in inflammatory bowel disease.
Bergman R; Parkes M
Aliment Pharmacol Ther; 2006 Apr; 23(7):841-55. PubMed ID: 16573787
[TBL] [Abstract][Full Text] [Related]
11. Drug insight: aminosalicylates for the treatment of IBD.
Nielsen OH; Munck LK
Nat Clin Pract Gastroenterol Hepatol; 2007 Mar; 4(3):160-70. PubMed ID: 17339853
[TBL] [Abstract][Full Text] [Related]
12. Oral mesalazine for the treatment of Crohn's disease: clinical efficacy with respect to pharmacokinetic properties.
Tromm A; Griga T; May B
Hepatogastroenterology; 1999; 46(30):3124-35. PubMed ID: 10626173
[TBL] [Abstract][Full Text] [Related]
13. Drug therapy: dose-response relationship of oral mesalazine in inflammatory bowel disease.
Mulder CJ; van den Hazel SJ
Mediators Inflamm; 1998; 7(3):135-6. PubMed ID: 9705596
[TBL] [Abstract][Full Text] [Related]
14. Mesalazine as a maintenance treatment in Crohn's disease.
Sutherland LR; Steinhart AH
Gut; 1998 Jan; 42(1):143-4. PubMed ID: 9505902
[No Abstract] [Full Text] [Related]
15. Development of a zero-order sustained-release tablet containing mesalazine and budesonide intended to treat the distal gastrointestinal tract in inflammatory bowel disease.
Gareb B; Eissens AC; Kosterink JGW; Frijlink HW
Eur J Pharm Biopharm; 2016 Jun; 103():32-42. PubMed ID: 27000751
[TBL] [Abstract][Full Text] [Related]
16. Decreased anti-Saccharomyces cerevisiae antibody titer by mesalazine in patients with Crohn's disease.
Oshitani N; Hato F; Matsumoto T; Jinno Y; Sawa Y; Hara J; Nakamura S; Seki S; Arakawa T; Kitano A; Kitagawa S; Kuroki T
J Gastroenterol Hepatol; 2000 Dec; 15(12):1400-3. PubMed ID: 11197050
[TBL] [Abstract][Full Text] [Related]
17. Crohn's Disease with Mesalazine Allergy that Was Difficult to Differentiate from Comorbid Ulcerative Colitis.
Tsuboi R; Matsumoto S; Miyatani H; Mashima H
Intern Med; 2019 Mar; 58(5):649-654. PubMed ID: 30333413
[TBL] [Abstract][Full Text] [Related]
18. Azathioprine versus mesalazine for prevention of postoperative clinical recurrence in patients with Crohn's disease with endoscopic recurrence: efficacy and safety results of a randomised, double-blind, double-dummy, multicentre trial.
Reinisch W; Angelberger S; Petritsch W; Shonova O; Lukas M; Bar-Meir S; Teml A; Schaeffeler E; Schwab M; Dilger K; Greinwald R; Mueller R; Stange EF; Herrlinger KR;
Gut; 2010 Jun; 59(6):752-9. PubMed ID: 20551460
[TBL] [Abstract][Full Text] [Related]
19. Mesalamine in the treatment of mild to moderate active Crohn's ileitis: results of a randomized, multicenter trial.
Prantera C; Cottone M; Pallone F; Annese V; Franzè A; Cerutti R; Bianchi Porro G
Gastroenterology; 1999 Mar; 116(3):521-6. PubMed ID: 10029609
[TBL] [Abstract][Full Text] [Related]
20. Obstructing Crohn's disease of the duodenum: is surgery always mandatory?
Karaoglu AO; Yukselen V
Int J Clin Pract; 2004 Feb; 58(2):221-3. PubMed ID: 15055874
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
